Commentary|Podcasts|February 20, 2026

The Pulse of Pharma Change in 2026

In this video episode, Pratap Khedkar, PhD, CEO of ZS, joins the Pharm Exec Podcast to discuss three distinct industry trends and strategy shifts converging at the moment amid the backdrop of US-driven global policy change.

Khedkar was elected CEO of ZS in July 2021. Prior to assuming the role, he led the firm’s global pharmaceuticals practice for nine years, as well as a practice focused on the dynamics of healthcare ecosystems. He founded and led its advanced data science capability track, which focuses on artificial intelligence. Khedkar has also served on ZS’s board since 2012.

A recognized healthcare industry expert, Khedkar is a past contributor to Pharm Exec and also regularly contributes his insights to publications including The Wall Street Journal, Bloomberg Businessweek, Business Insider, Fortune, Medical Marketing & Media, NPR, and others. His thought leadership work focuses on topics as diverse as healthcare policy, life sciences companies’ new commercial and organizational models, and the evolving relationships between patients, providers, payers, and manufacturers.

Khedkar holds a PhD in artificial intelligence from the University of California, Berkeley, and a Bachelor of Technology degree in computer science from the Indian Institute of Technology Delhi.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.